Monopar Therapeutics Inc. Common Stock
MNPRStock
$108.52+173.37%52W
Market Cap$714.92M
P/E—
Div yield—
Beta1.47
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)57.73%
Price vs S&P 500 (4W)73.73%
VGM Score86.34
Market Capitalization$714.92M
Earnings Surprise History
Q1 26-0.46est. -0.85
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.20
4.20
4.16
4.16
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MNPRMonopar Therapeutics Inc. Common Stock | — | — | A | $108.52 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapeutics with a diversified pipeline spanning multiple development stages. The company's programs include Validive for chemoradiotherapy-induced oral mucositis in oropharyngeal cancer, camsirubicin for soft tissue sarcoma, the preclinical antibody MNPR-101 for cancers and severe COVID-19, and the early-stage analog MNPR-202 for multiple cancer types.